208 related articles for article (PubMed ID: 36660064)
1. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Five-Year Retrospective Study in 10 Centers.
Gerodias FR; Tan MK; De Guzman A; Bernan A; Locnen SA; Apostol-Alday A; Ybanez EJ; Magno JD; Lim A; Junia A; Mambulao R; Cosare-San Pedro J; Lucero J; Quijano Z; Apurillo J; Uson AJ; Lim JL; Inso CA; Agoncillo-Infante A; Bongcawil RY; Fernando GY; Ramos-Manalaysay AM; Arellano-Simon FA; Ilagan-Cargullo EM; Bago-Azares MJ; Baterna J; Tapispisan JA; Masadao-Rodriguez NM; Tarranza JL; Lista LS; Gumapon JK
Cardiol Res; 2022 Dec; 13(6):380-392. PubMed ID: 36660064
[TBL] [Abstract][Full Text] [Related]
2. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of Global Longitudinal Strain and NT-proBNP on Early Development of Cardiotoxicity in Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.
Muckiene G; Vaitiekus D; Zaliaduonyte D; Zabiela V; Verseckaite-Costa R; Vaiciuliene D; Juozaityte E; Jurkevicius R
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241185
[No Abstract] [Full Text] [Related]
4. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
5. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series.
Ganatra S; Nohria A; Shah S; Groarke JD; Sharma A; Venesy D; Patten R; Gunturu K; Zarwan C; Neilan TG; Barac A; Hayek SS; Dani S; Solanki S; Mahmood SS; Lipshultz SE
Cardiooncology; 2019; 5():1. PubMed ID: 32154008
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis.
Sandamali JAN; Hewawasam RP; Fernando MACSS; Jayatilaka KAPW; Madurawe RD; Sathananthan PP; Ekanayake U; Horadugoda J
Biomed Res Int; 2020; 2020():1847159. PubMed ID: 33274195
[TBL] [Abstract][Full Text] [Related]
7. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Polymorphisms in ATP-Binding Cassette Transporter Genes on Anthracycline-Induced Early Cardiotoxicity in Patients with Breast Cancer.
Muckiene G; Vaitiekus D; Zaliaduonyte D; Bartnykaite A; Plisiene J; Zabiela V; Juozaityte E; Jurkevicius R
J Cardiovasc Dev Dis; 2023 May; 10(6):. PubMed ID: 37367397
[TBL] [Abstract][Full Text] [Related]
9. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
[TBL] [Abstract][Full Text] [Related]
10. BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer.
Lu X; Zhao Y; Chen C; Han C; Xue L; Xing D; Huang O; Tao M
Oncol Lett; 2019 Nov; 18(5):4992-5001. PubMed ID: 31612011
[TBL] [Abstract][Full Text] [Related]
11. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Pearson EJ; Nair A; Daoud Y; Blum JL
Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
[TBL] [Abstract][Full Text] [Related]
12. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.
Peddi P; Master SR; Dwary AD; Ravipati HP; Patel AH; Pasam A; Katikaneni PK; Shi R; Burton GV; Chu QD
Breast J; 2019 Jan; 25(1):62-68. PubMed ID: 30592128
[TBL] [Abstract][Full Text] [Related]
13. Increased EAT volume after anthracycline chemotherapy is associated with a low risk of cardiotoxicity in breast cancer.
Kwon SS; Nam BD; Lee MY; Lee MH; Lee J; Park BW; Bang DW; Kwon SH
Breast Cancer Res Treat; 2022 Nov; 196(1):111-119. PubMed ID: 36045270
[TBL] [Abstract][Full Text] [Related]
14. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Anthracycline-Induced Cardiotoxicity.
Qiu S; Zhou T; Qiu B; Zhang Y; Zhou Y; Yu H; Zhang J; Liu L; Yuan L; Yang G; Duan Y; Xing C
Front Cardiovasc Med; 2021; 8():736854. PubMed ID: 34660739
[No Abstract] [Full Text] [Related]
16. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
[TBL] [Abstract][Full Text] [Related]
17. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
18. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
[TBL] [Abstract][Full Text] [Related]
19. Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry).
Inoue K; Iida N; Tajiri K; Bando H; Chiba S; Tasaka N; Nagashio K; Sasamura R; Naito H; Murata M; Li S; Ishizu T; Nakazawa Y; Sekine I; Ieda M
J Clin Med; 2021 Mar; 10(7):. PubMed ID: 33801734
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
